MindWalk Holdings Corp.
HYFT
NASDAQ·Healthcare·Biotechnology·Mkt cap $62.0M
$1.32
▼ -0.75%
P/E
-5.92
Mkt Cap
$62.0M
52-Wk Range
$0.99–$2.99
52-Week Range
$0.99 - $2.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 28.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI and multi-omics integration technology
- Unique bio-native AI approach combining laboratory science with machine learning
- Strategic partnerships with major pharmaceutical and biotechnology companies
- First-mover advantage in AI-powered biologics discovery
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Increasing adoption of AI in drug discovery and development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-17.5% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HYFT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 21, 2026
JUL 22, 2026
Reported EPS of -$0.06 vs -$0.05 consensus (-12.8% surprise). Revenue of $3.0M vs $3.2M expected (-6.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-12.8%
Revenue trend · last 8Q
—
—
—
+4%
+26%
+53%
-36%
-42%
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
Q4 26
$1.8M
$2.0M
$4.7M
$5.0M
$2.3M
$3.1M
$3.0M
$2.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
-93.9%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · $5.00 · May 20, 2026
vs Industry
How HYFT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related